Investigating apoptosis in peripheral blood mononuclear cells among the elderly in the post-COVID-19 era, 2025, Abiri and Hemmatian

SNT Gatchaman

Senior Member (Voting Rights)
Staff member
Investigating apoptosis in peripheral blood mononuclear cells among the elderly in the post-COVID-19 era
Abiri, Elaheh; Hemmatian, Najmeh

BACKGROUND AND AIM
The COVID-19 pandemic has left a lasting imprint on immune function, particularly in the elderly—a population already vulnerable to immunosenescence. While acute and long-COVID immune responses have been widely studied, the long-term apoptotic behavior of peripheral blood mononuclear cells (PBMCs) remains underexplored. This study aims to investigate the legacy of SARS-CoV-2 on PBMC apoptosis in elderly individuals during the post-COVID era, shedding light on potential persistent immune dysregulation.

MATERIALS AND METHODS
In this cross-sectional study, PBMCs were isolated from peripheral blood samples of elderly individuals (> 65 years old) with a documented history of COVID-19 infection at least six months prior. Using multiparametric flow cytometry, we quantified early and late apoptosis markers (Annexin V/PI), mitochondrial membrane potential disruption (ΔΨm), and expression of pro-apoptotic (Bax, Caspase-3) and anti-apoptotic (Bcl-2) proteins. Statistical analyses were performed to assess intergroup differences and correlations with clinical history. This study was conducted in 2025.

RESULTS
Elderly post-COVID individuals exhibited a significantly elevated proportion of apoptotic PBMCs compared to controls (p < 0.01), particularly within the CD4 + and CD8 + T-cell subsets. Mitochondrial depolarization and increased Bax/Bcl-2 ratios indicated a shift toward intrinsic apoptotic pathways. Caspase-3 activation was also heightened in the post-COVID group. Notably, apoptotic burden correlated with time since infection and severity of initial illness.

DISCUSSION
Our findings suggest a prolonged apoptotic signature in the immune cells of elderly individuals following recovery from COVID-19. These alterations may reflect a sustained immune exhaustion or maladaptive remodeling of lymphocyte populations, potentially contributing to impaired immunosurveillance and increased vulnerability to secondary infections or chronic inflammatory conditions.

CONCLUSION
COVID-19 may cast a long immunological shadow in the elderly, with persistent PBMC apoptosis representing a novel facet of post-viral immune dysregulation. Flow cytometry reveals a unique apoptotic phenotype that could serve as a biomarker for long-term immune health and guide post-pandemic clinical management strategies for aging populations.

Web | PDF | BMC Immunology | Open Access
 
A key strength of our study is the deliberate exclusion of individuals with ongoing long COVID symptoms. This distinction is essential because immune dysregulation and chronic inflammation have been reported in symptomatic long COVID cohorts, which could confound interpretation of apoptosis-related findings. By focusing on elderly donors who had clinically recovered from COVID-19 and remained asymptomatic for at least six months, our results demonstrate that a sustained pro-apoptotic phenotype in PBMCs can persist even in the absence of long COVID.
 
Back
Top Bottom